IL-33 induces both regulatory B cells and regulatory T cells in dextran sulfate sodium-induced colitis

International Immunopharmacology

Volumn 46, Issue , 2017, Pages 38-47

  Zhu, Junfeng ^a,c   Xu, Ying ^b   Zhu, Chunyu ^a   Zhao, Jian ^a   Meng, Xinrui ^a   Chen, Siyao ^a   Wang, Tianqi ^a   Li, Xue ^a   Zhang, Li ^a   Lu, Changlong ^c   Liu, Hongsheng ^a   Sun, Xun ^c  

^a LIAONING UNIVERSITY   (China)

^b Northeast Pharmaceutical Group Co Ltd   (China)

^c CHINA MEDICAL UNIVERSITY   (China)

Author keywords

IL 33; Inflammatory bowel diseases; Regulatory B cell; Regulatory T cell

Indexed keywords

DEXTRAN SULFATE; INTERLEUKIN 1 RECEPTOR LIKE 1 PROTEIN; INTERLEUKIN 33; CYTOKINE; IL1RL1 PROTEIN, MOUSE; IL33 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; BIOLOGICAL THERAPY; COLITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DISEASE ACTIVITY; DISEASE PREDISPOSITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HISTOLOGY; IMMUNOMODULATION; MACROPHAGE; MALE; MESENTERY LYMPH NODE; MOUSE; NONHUMAN; OCCULT BLOOD; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECTUM HEMORRHAGE; REGULATORY T LYMPHOCYTE; TH1 CELL; TH2 CELL; WEIGHT REDUCTION; ANIMAL; C57BL MOUSE; CELL CULTURE; CHEMICALLY INDUCED; COLON; DISEASE MODEL; GENETICS; HUMAN; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASE; METABOLISM; REGULATORY B LYMPHOCYTE; SIGNAL TRANSDUCTION; TH1 TH2 BALANCE;

ANIMALS; B-LYMPHOCYTES, REGULATORY; CELLS, CULTURED; COLITIS; COLON; CYTOKINES; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-1 RECEPTOR-LIKE 1 PROTEIN; INTERLEUKIN-33; MALE; MICE; MICE, INBRED C57BL; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; TH1-TH2 BALANCE; TH2 CELLS;

EID: 85014075048     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2017.02.006     Document Type: Article

References (58)

1. [1] de Souza, H.S., Fiocchi, C., Immunopathogenesis of IBD: current state of the art. Nat. Rev. Gastroenterol. Hepatol. 13 (2016), 13–27.
2. [2] Xavier, R.J., Podolsky, D.K., Unravelling the pathogenesis of inflammatory bowel disease. Nature 448 (2007), 427–434.
3. [3] Weaver, C.T., Hatton, R.D., Interplay between the TH17 and TReg cell lineages: a (co-)evolutionary perspective. Nat. Rev. Immunol. 9 (2009), 883–889.
4. [4] Schmitz, J., Owyang, A., Oldham, E., Song, Y., Murphy, E., McClanahan, T.K., et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23 (2005), 479–490.
5. [5] Moussion, C., Ortega, N., Girard, J.P., The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel ‘alarmin’?. PLoS One, 3, 2008, e3331.
6. [6] Carriere, V., Roussel, L., Ortega, N., Lacorre, D.A., Americh, L., Aguilar, L., et al. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc. Natl. Acad. Sci. U. S. A. 104 (2007), 282–287.
7. [7] Iwahana, H., Yanagisawa, K., Ito-Kosaka, A., Kuroiwa, K., Tago, K., Komatsu, N., et al. Different promoter usage and multiple transcription initiation sites of the interleukin-1 receptor-related human ST2 gene in UT-7 and TM12 cells. Eur. J. Biochem. 264 (1999), 397–406.
8. [8] Dinarello, C.A., Immunological and inflammatory functions of the interleukin-1 family. Annu. Rev. Immunol. 27 (2009), 519–550.
9. [9] O'Neill, L.A.J., The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of progress. Immunol. Rev. 226 (2008), 10–18.
10. [10] Sundnes, O., Pietka, W., Loos, T., Sponheim, J., Rankin, A.L., Pflanz, S., et al. Epidermal expression and regulation of interleukin-33 during homeostasis and inflammation: strong species differences. J. Invest. Dermatol. 135 (2015), 1771–1780.
11. [11] Zhao, Q., Chen, G., Role of IL-33 and its receptor in T cell-mediated autoimmune diseases. Biomed. Res. Int., 2014, 2014, 10.
12. [12] Luo, Y., Zhou, Y., Xiao, W., Liang, Z., Dai, J., Weng, X., et al. Interleukin-33 ameliorates ischemic brain injury in experimental stroke through promoting Th2 response and suppressing Th17 response. Brain Res. 1597 (2015), 86–94.
13. [13] Jiang, H.R., Milovanovic, M., Allan, D., Niedbala, W., Besnard, A.G., Fukada, S.Y., et al. IL-33 attenuates EAE by suppressing IL-17 and IFN-gamma production and inducing alternatively activated macrophages. Eur. J. Immunol. 42 (2012), 1804–1814.
14. [14] Komai-Koma, M., Xu, D., Li, Y., McKenzie, A.N., McInnes, I.B., Liew, F.Y., IL-33 is a chemoattractant for human Th2 cells. Eur. J. Immunol. 37 (2007), 2779–2786.
15. [15] Smithgall, M.D., Comeau, M.R., Yoon, B.R., Kaufman, D., Armitage, R., Smith, D.E., IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells. Int. Immunol. 20 (2008), 1019–1030.
16. [16] Bourgeois, E., Van, L.P., Samson, M., Diem, S., Barra, A., Roga, S., et al. The pro-Th2 cytokine IL-33 directly interacts with invariant NKT and NK cells to induce IFN-gamma production. Eur. J. Immunol. 39 (2009), 1046–1055.
17. [17] Pushparaj, P.N., Li, D., Komai-Koma, M., Guabiraba, R., Alexander, J., McSharry, C., et al. Interleukin-33 exacerbates acute colitis via interleukin-4 in mice. Immunology 140 (2013), 70–77.
18. [18] Sedhom, M.A., Pichery, M., Murdoch, J.R., Foligné, B., Ortega, N., Normand, S., et al. Neutralisation of the interleukin-33/ST2 pathway ameliorates experimental colitis through enhancement of mucosal healing in mice. Gut 62 (2013), 1714–1723.
19. [19] Pastorelli, L., Garg, R.R., Hoang, S.B., Spina, L., Mattioli, B., Scarpa, M., et al. Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 8017–8022.
20. [20] De Salvo, C., Wang, X.M., Pastorelli, L., Mattioli, B., Omenetti, S., Buela, K.A., et al. IL-33 drives eosinophil infiltration and pathogenic type 2 helper T-cell immune responses leading to chronic experimental ileitis. Am. J. Pathol., 2016.
21. [21] Waddell, A., Vallance, J.E., Moore, P.D., Hummel, A.T., Wu, D., Shanmukhappa, S.K., et al. IL-33 signaling protects from murine oxazolone colitis by supporting intestinal epithelial function. Inflamm. Bowel Dis. 21 (2015), 2737–2746.
22. [22] Monticelli, L.A., Osborne, L.C., Noti, M., Tran, S.V., Zaiss, D.M., Artis, D., IL-33 promotes an innate immune pathway of intestinal tissue protection dependent on amphiregulin–EGFR interactions. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), 10762–10767.
23. [23] Duan, L., Chen, J., Zhang, H., Yang, H., Zhu, P., Xiong, A., et al. Interleukin-33 ameliorates experimental colitis through promoting Th2/Foxp3(+) regulatory T-cell responses in mice. Mol. Med. 18 (2012), 753–761.
24. [24] Saadah, O.I., Al-Harthi, S.E., Al-Mughales, J.A., Bin-Taleb, Y.Y., Baeshen, R.S., Serum interleukin-33 level in Saudi children with inflammatory bowel disease. Int. J. Clin. Exp. Pathol. 8 (2015), 16000–16006.
25. [25] Menegat, J.S., Lira-Junior, R., Siqueira, M.A., Brito, F., Carvalho, A.T., Fischer, R.G., et al. Cytokine expression in gingival and intestinal tissues of patients with periodontitis and inflammatory bowel disease: an exploratory study. Arch. Oral Biol. 66 (2016), 141–146.
26. [26] Sponheim, J., Pollheimer, J., Olsen, T., Balogh, J., Hammarstrom, C., Loos, T., et al. Inflammatory bowel disease-associated interleukin-33 is preferentially expressed in ulceration-associated myofibroblasts. Am. J. Pathol. 177 (2010), 2804–2815.
27. [27] Beltrán, C.J., Núñez, L.E., Díaz-Jiménez, D., Farfan, N., Candia, E., Heine, C., et al. Characterization of the novel ST2/IL-33 system in patients with inflammatory bowel disease. Inflamm. Bowel Dis. 16 (2010), 1097–1107.
28. [28] Kobori, A., Yagi, Y., Imaeda, H., Ban, H., Bamba, S., Tsujikawa, T., et al. Interleukin-33 expression is specifically enhanced in inflamed mucosa of ulcerative colitis. J. Gastroenterol. 45 (2010), 999–1007.
29. [29] Seidelin, J.B., Bjerrum, J.T., Coskun, M., Widjaya, B., Vainer, B., Nielsen, O.H., IL-33 is upregulated in colonocytes of ulcerative colitis. Immunol. Lett. 128 (2010), 80–85.
30. [30] Miller, A.M., Role of IL-33 in inflammation and disease. J. Inflamm., 8, 2011, 22.
31. [31] Knight, A.K., Blázquez, A.B., Zhang, S., Mayer, L., Sampson, H.A., Berin, M.C., CD4 T cells activated in the mesenteric lymph node mediate gastrointestinal food allergy in mice. Am. J. Physiol. Gastrointest. Liver Physiol. 293 (2007), G1234–G1243.
32. [32] Cooper, H.S., Murthy, S.N., Shah, R.S., S, D.J., Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab. Investig. 69 (1993), 238–249.
33. [33] Sun, X., Somada, S., Shibata, K., Muta, H., Yamada, H., Yoshihara, H., et al. A critical role of CD30 ligand/CD30 in controlling inflammatory bowel diseases in mice. Gastroenterology 134 (2008), 447–458.
34. [34] Komai-Koma, M., Wang, E., Kurowska-Stolarska, M., Li, D., McSharry, C., Xu, D., Interleukin-33 promoting Th1 lymphocyte differentiation dependents on IL-12. Immunobiology 221 (2016), 412–417.
35. + T cells and promotes allergic-induced airway inflammation independent of IL-4. J. Immunol. 181 (2008), 4780–4790.
36. [36] Cherry, W.B., Yoon, J., Bartemes, K.R., Iijima, K., Kita, H., A novel IL-1 family cytokine, IL-33, potently activates human eosinophils. J. Allergy Clin. Immunol. 121 (2008), 1484–1490.
37. [37] Suzukawa, Maho, Iikura, Motoyasu, Koketsu, Rikiya, Nagase, Hiroyuki, Tamura, Chise, Komiya, Akiko, et al. An IL-1 cytokine member, IL-33, induces human basophil activation via its ST2 receptor. J. Immunol. 181 (2008), 5981–5989.
38. [38] Rank, M.A., Kobayashi, T., Kozaki, H., Bartemes, K.R., Squillace, D.L., Kita, H., IL-33-activated dendritic cells induce an atypical TH2-type response. J. Allergy Clin. Immunol. 123 (2009), 1047–1054.
39. [39] Kurowska-Stolarska, M., Stolarski, B., Kewin, P., Murphy, G., Corrigan, C.J., Ying, S., et al. IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation. J. Immunol. 183 (2009), 6469–6477.
40. [40] Alves-Filho, J.C., Sonego, F., Souto, F.O., Freitas, A., Verri, W.A. Jr., Auxiliadora-Martins, M., et al. Interleukin-33 attenuates sepsis by enhancing neutrophil influx to the site of infection. Nat. Med. 16 (2010), 708–712.
41. [41] Bartemes, K.R., Iijima, K., Kobayashi, T., Kephart, G.M., McKenzie, A.N., Kita, H., IL-33-responsive lineage- CD25 + CD44(hi) lymphoid cells mediate innate type 2 immunity and allergic inflammation in the lungs. J. Immunol. 188 (2012), 1503–1513.
42. [42] Mjösberg, J., Bernink, J., Golebski, K., Karrich Julien, J., Peters Charlotte, P., Blom, B., et al. The transcription factor GATA3 is essential for the function of human type 2 innate lymphoid cells. Immunity 37 (2012), 649–659.
43. [43] Hoyler, T., Klose, C.S.N., Souabni, A., TurquetiNeves, A., Pfeifer, D., Rawlins, E.L., et al. The transcription factor GATA-3 controls cell fate and maintenance of type 2 innate lymphoid cells. Immunity 37 (2012), 634–648.
44. [44] Okayasu, I., Hatakeyama, S., Yamada, M., Ohkusa, T., Inagaki, Y., Nakaya, R., A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 98 (1990), 694–702.
45. [45] Murphy, K.M., Reiner, S.L., The lineage decisions of helper T cells. Nat. Rev. Immunol. 2 (2002), 933–944.
46. [46] Ansel, K.M., Djuretic, I., Tanasa, B., Rao, A., Regulation of Th2 differentiation and Il4 locus accessibility. Annu. Rev. Immunol. 24 (2006), 607–656.
47. [47] Izcue, A., Coombes, J.L., Powrie, F., Regulatory lymphocytes and intestinal inflammation. Annu. Rev. Immunol. 27 (2009), 313–338.
48. [48] Yamada, A., Arakaki, R., Saito, M., Tsunematsu, T., Kudo, Y., Ishimaru, N., Role of regulatory T cell in the pathogenesis of inflammatory bowel disease. World J. Gastroenterol. 22 (2016), 2195–2205.
49. [49] Matta, B.M., Turnquist, H.R., Expansion of regulatory T cells in vitro and in vivo by IL-33. Methods Mol. Biol. 1371 (2016), 29–41.
50. [50] Matta, B.M., Lott, J.M., Mathews, L.R., Liu, Q., Rosborough, B.R., Blazar, B.R., et al. IL-33 is an unconventional alarmin that stimulates IL-2 secretion by dendritic cells to selectively expand IL-33R/ST2 + regulatory T cells. J. Immunol. 193 (2014), 4010–4020.
51. [51] Schiering, C., Krausgruber, T., Chomka, A., Frohlich, A., Adelmann, K., Wohlfert, E.A., et al. The alarmin IL-33 promotes regulatory T-cell function in the intestine. Nature 513 (2014), 564–568.
52. [52] Alex, P., Zachos, N.C., Nguyen, T., Gonzales, L., Chen, T.E., Conklin, L.S., et al. Distinct cytokine patterns identified from multiplex profiles of murine DSS and TNBS-induced colitis. Inflamm. Bowel Dis. 15 (2009), 341–352.
53. [53] Wei, B., Velazquez, P., Turovskaya, O., Spricher, K., Aranda, R., Kronenberg, M., et al. Mesenteric B cells centrally inhibit CD4 + T cell colitis through interaction with regulatory T cell subsets. Proc. Natl. Acad. Sci. U. S. A. 102 (2005), 2010–2015.
54. [54] Carter, N.A., Vasconcellos, R., Rosser, E.C., Tulone, C., Munoz-Suano, A., Kamanaka, M., et al. Mice lacking endogenous IL-10-producing regulatory B cells develop exacerbated disease and present with an increased frequency of Th1/Th17 but a decrease in regulatory T cells. J. Immunol., 186, 2011.
55. [55] Carter, N.A., Rosser, E.C., Mauri, C., Interleukin-10 produced by B cells is crucial for the suppression of Th17/Th1 responses, induction of T regulatory type 1 cells and reduction of collagen-induced arthritis. Arthritis Res. Ther. 14 (2012), 1–9.
56. [56] Mishima, Y., Ishihara, S., Aziz, M.M., Oka, A., Kusunoki, R., Otani, A., et al. Decreased production of interleukin-10 and transforming growth factor-beta in Toll-like receptor-activated intestinal B cells in SAMP1/Yit mice. Immunology 131 (2010), 473–487.
57. [57] Sattler, S., Ling, G.S., Xu, D., Hussaarts, L., Romaine, A., Zhao, H., et al. IL-10-producing regulatory B cells induced by IL-33 (Breg(IL-33)) effectively attenuate mucosal inflammatory responses in the gut. J. Autoimmun. 50 (2014), 107–122.
58. [58] Amu, S., Saunders, S.P., Kronenberg, M., Mangan, N.E., Atzberger, A., Fallon, P.G., Regulatory B cells prevent and reverse allergic airway inflammation via FoxP3-positive T regulatory cells in a murine model. J. Allergy Clin. Immunol. 125 (2010), 1114–1124.